ALLO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

ALLO ▼ -7.83% at T+5d

NEUTRAL call ✗ call lost -7.83% · α vs SPY -7.54% · entry $2.17 → $2.00

Next anchor: T+20d in 16d

Last close $1.85 (close Jun 8) · -14.75% from $2.17 entry

Entry anchored
May 28, 04:48 PM ET
via Databento tick

T+1d

-0.92%

call -0.92% · α -1.20%

$2.15

settled 12d ago

T+5d

-7.83%

call -7.83% · α -7.54%

$2.00

settled 6d ago

T+20d

—

call — · α —

—

in 16d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Allogene Therapeutics announced a planned CEO transition: Dr. David Chang will step down as President and CEO effective June 30, 2026, and will be succeeded by Dr. Zachary Roberts, the current EVP of R&D and CMO, effective July 1, 2026. This is a routine leadership succession event with no material financial impact — the company remains on its existing clinical development path.

Actionable Insight

Monitor the ALPHA3 trial data readout and any pipeline updates under the new CEO. The transition is orderly and internal, suggesting continuity — no immediate trading catalyst.

Key Facts

Dr. David Chang to transition from President and CEO effective June 30, 2026, after eight years of leadership.
Dr. Zachary Roberts, EVP of R&D and CMO, appointed President and CEO effective July 1, 2026, and to the Board.
Dr. Chang will continue to serve on the Board of Directors.
Dr. Roberts joined Allogene in January 2023 and led the design of the pivotal ALPHA3 trial in first-line LBCL.
No financial terms, severance, or compensation changes were disclosed in the press release.

Financial Impact

No financial impact disclosed — leadership transition is routine and planned.

Risk Factors

Potential strategic shift under new CEO, though Dr. Roberts was already leading R&D.
No financial details provided — any undisclosed compensation or severance could emerge in subsequent filings.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

86% bullish (21 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3303320

15 reports for ALLO

T+1T+5T+20T+60

71% Hit rate 5 of 7 directional calls best @ T+5▲ +10.14%Apr 15, 2026

Filters

Reports for ALLO — sortable, filterable
	Type				Now
May 28, 2026 12d ago	DEFA14A NEUTRAL ★ 3/10	$2.17 $1.88	▼ −13.36%	▼ −10.84%	$1.85 (−14.75%)
May 28, 2026 12d ago	8-K NEUTRAL ★ 3/10	$2.17 $1.88	▼ −13.36%	▼ −10.84%	$1.85 (−14.75%)
May 28, 2026 12d ago	Press Release NEUTRAL ★ 3/10	$2.17 $2.00	▼ −7.83%	▼ −7.54%	$1.85 (−14.75%)
Apr 21, 2026 7w ago	Press Release BULLISH ★ 7/10	$2.32 $2.19	▼ −5.60%	▼ −6.69%	$1.85 (−20.26%)
Apr 15, 2026 7w ago	8-K NEUTRAL ★ 5/10	$2.37 $2.35	▼ −0.84%	▼ −1.83%	$1.85 (−21.94%)
Apr 15, 2026 7w ago	424B5 BEARISH ★ 7/10	$2.37 $2.35	▲ +0.84%	▲ +1.83%	$1.85 (+21.94%)
Apr 15, 2026 7w ago	Press Release BULLISH ★ 7/10	$2.17 $2.39	▲ +10.14%	▲ +8.50%	$1.85 (−14.75%)
Apr 15, 2026 8w ago	Press Release BEARISH ★ 6/10	$2.17 $2.39	▼ −10.14%	▼ −8.50%	$1.85 (+14.75%)
Apr 13, 2026 8w ago	424B5 MIXED ★ 6/10	$2.28 $2.32	▲ +1.75%	▲ +0.36%	$1.85 (−18.86%)
Apr 13, 2026 8w ago	8-K BEARISH ★ 7/10	$2.28 $2.32	▼ −1.75%	▼ −0.36%	$1.85 (+18.86%)

US Market Status

Market Closed — Opens in 5h 46m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access